Condition: Hematologic Malignancy · Sponsor: University Hospital Tuebingen
The purpose of this clinical trial is to examine safety and toxicity of CD45RA depleted donor lymphocyte infusion (DLI) after transplantation of TCRα/β/CD19 depleted peripheral blood stem cells.
This description comes directly from the study's public registry record.
Wolfgang Bethge, MD, PhD · +49 7071 29-83176 · wolfgang.bethge@med.uni-tuebingen.de
Peter Lang, MD, PhD · +49 7071 29-81386 · peter.lang@med.uni-tuebingen.de
Always discuss trial participation with your own doctor first.
| University Children's Hospital University Clinic Tuebingen | Tübingen, Germany | Recruiting |
| University Hospital Tuebingen, Department of Hematology, Oncology, Immunology and Rheumatology | Tübingen, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05943067